New perspectives in liquid biopsy for glioma patients.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
13
9
2022
medline:
15
10
2022
entrez:
12
9
2022
Statut:
ppublish
Résumé
Gliomas are the most common primary tumors of the central nervous system. They are characterized by a disappointing prognosis and ineffective therapy that has shown no substantial improvements in the past 20 years. The lack of progress in treating gliomas is linked with the inadequacy of suitable tumor samples to plan translational studies and support laboratory developments. To overcome the use of tumor tissue, this commentary review aims to highlight the potential for the clinical application of liquid biopsy (intended as the study of circulating biomarkers in the blood), focusing on circulating tumor cells, circulating DNA and circulating noncoding RNA. Thanks to the increasing sensitivity of sequencing techniques, it is now possible to analyze circulating nucleic acids and tumor cells (liquid biopsy). Although studies on the use of liquid biopsy are still at an early stage, the potential clinical applications of liquid biopsy in the study of primary brain cancer are many and have the potential to revolutionize the approach to neuro-oncology, and importantly, they offer the possibility of gathering information on the disease at any time during its history.
Identifiants
pubmed: 36093876
doi: 10.1097/CCO.0000000000000902
pii: 00001622-202211000-00016
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
RNA, Untranslated
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
705-712Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424.
Grech N, Dalli T, Mizzi S, et al. Rising incidence of glioblastoma multiforme in a well defined population. Cureus 2020; 12:e8195.
Rasmussen BK, Hansen S, Laursen RJ, et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I−IV in the the Danish Neuro-Oncology Registry. J Neurooncol 2017; 135:571–579.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021; 23:1231–1251.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987–996.
Lombardi G, Barresi V, Castellano A, et al. Clinical management of diffuse low-grade gliomas. Cancers (Basel) 2020; 12:308.
Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021; 18:170–186.
Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110:4009–4014.
Brennan PM, Borchert R, Coulter C, et al. Second surgery for progressive glioblastoma: a multicentre questionnaire and cohort-based review of clinical decision-making and patient outcomes in current practice. J Neurooncol 2021; 153:99–107.
Pasqualetti F, Montemurro N, Desideri I, et al. Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma. Acta Neurol Belg 2021; 122:441–446.
Bette S, Barz M, Huber T, et al. Retrospective analysis of radiological recurrence patterns in glioblastoma, their prognostic value and association to postoperative infarct volume. Sci Rep 2018; 8:4561.
Liu X, Chen X, Shi L, et al. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. J Exp Clin Cancer Res 2019; 38:219.
Vaglini F, Pardini C, Di Desidero T, et al. Melanocortin receptor-4 and glioblastoma cells: effects of the selective antagonist ML00253764 alone and in combination with temozolomide in vitro and in vivo. Mol Neurobiol 2018; 55:4984–4997.
Towner RA, Smith N, Saunders D, et al. OKN-007 increases temozolomide (TMZ) sensitivity and suppresses TMZ-resistant glioblastoma (GBM) tumor growth. Transl Oncol 2019; 12:320–335.
Alix-Panabières C, Pantel K. Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. Ann Transl Med 2013; 1:18.
Müller Bark J, Kulasinghe A, Chua B, et al. Circulating biomarkers in patients with glioblastoma. Br J Cancer 2020; 122:295–305.
Olioso D, Caccese M, Santangelo A, et al. Serum exosomal microRNA-21, 222 and 124-3p as noninvasive predictive biomarkers in newly diagnosed high-grade gliomas: a prospective study. Cancers (Basel) 2021; 13:3006.
Navarria P, Minniti G, Clerici E, et al. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). J Neurooncol 2019; 142:59–67.
Aldape K, Brindle KM, Chesler L, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol 2019; 16:509–520.
Pasqualetti F, Restante G, Gonnelli A, et al. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. Neuro Oncol 2019; 21:1610–1611.
Chen L, Bode AM, Dong Z. Circulating tumor cells: moving biological insights into detection. Theranostics 2017; 7:2606–2619.
Cabel L, Proudhon C, Gortais H, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol 2017; 22:421–430.
Tong B, Xu Y, Zhao J, et al. Prognostic significance of circulating tumor cells in nonsmall cell lung cancer patients undergoing chemotherapy. Oncotarget 2017; 8:86615–86624.
Lorente D, Olmos D, Mateo J, et al. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann Oncol 2018; 29:1554–1560.
Gatto L, Franceschi E, Di Nunno V, et al. Liquid biopsy in glioblastoma management: from current research to future perspectives. Oncologist 2021; 26:865–878.
Macarthur KM, Kao GD, Chandrasekaran S, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res 2014; 74:2152–2159.
Müller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 2014; 6:247ra101.
Sullivan JP, Nahed BV, Madden MW, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 2014; 4:1299–1309.
Gao F, Cui Y, Jiang H, et al. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget 2016; 7:71330–71340.
Krol I, Castro-Giner F, Maurer M, et al. Detection of circulating tumour cell clusters in human glioblastoma. Br J Cancer 2018; 119:487–491.
Bang-Christensen SR, Pedersen RS, Pereira MA, et al. Capture and detection of circulating glioma cells using the recombinant VAR2CSA malaria protein. Cells 2019; 8:998.
David L. Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting. Appl Sci 2020; 10:338.
Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32:579–586.
Ignatiadis M, Lee M, Jeffrey SS. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res 2015; 21:4786–4800.
Mair R, Mouliere F. Cell-free DNA technologies for the analysis of brain cancer. Br J Cancer 2022; 126:371–378.
Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease − latest advances and implications for cure. Nat Rev Clin Oncol 2019; 16:409–424.
Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 2016; 34:2404–2415.
Seoane J, De Mattos-Arruda L, Le Rhun E, et al. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol 2019; 30:211–218.
Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017; 14:531–548.
Eibl RH, Schneemann M. Liquid biopsy and primary brain tumors. Cancers (Basel) 2021; 13:5429.
Schwaederle M, Chattopadhyay R, Kato S, et al. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Res 2017; 77:5419–5427.
Nassiri F, Chakravarthy A, Feng S, et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. Nat Med 2020; 26:1044–1047.
Sabedot TS, Malta TM, Snyder J, et al. A serum-based DNA methylation assay provides accurate detection of glioma. Neuro Oncol 2021; 23:1494–1508.
Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6:224ra24.
Bos MK, Nasserinejad K, Jansen MPHM, et al. Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. Mol Oncol 2021; 15:57–66.
Deveson IW, Gong B, Lai K, et al. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol 2021; 39:1115–1128.
Hudecova I. Digital PCR analysis of circulating nucleic acids. Clin Biochem 2015; 48:948–956.
Gorgannezhad L, Umer M, Islam MN, et al. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. Lab Chip 2018; 18:1174–1196.
Cheng J, Meng J, Zhu L, et al. Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications. Mol Cancer 2020; 19:66.
He X, Qi Y, Zhang X, et al. Current landscape of tumor-derived exosomal ncRNAs in glioma progression, detection, and drug resistance. Cell Death Dis 2021; 12:1145.
Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108:5003–5008.
Geekiyanage H, Rayatpisheh S, Wohlschlegel JA, et al. Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides. Proc Natl Acad Sci USA 2020; 117:24213–24223.
Matsumoto J, Stewart T, Banks WA, et al. The transport mechanism of extracellular vesicles at the blood-brain barrier. Curr Pharm Des 2017; 23:6206–6214.
Santangelo A, Tamanini A, Cabrini G, et al. Circulating microRNAs as emerging noninvasive biomarkers for gliomas. Ann Transl Med 2017; 5:277.
Garcia CM, Toms SA. The role of circulating microRNA in glioblastoma liquid biopsy. World Neurosurg 2020; 138:425–435.
Choppavarapu L, Kandi SM. Circulating microRNAs as potential biomarkers in glioma: a mini-review. Endocr Metab Immune Disord Drug Targets 2021; 21:195–202.
Kristensen LS, Jakobsen T, Hager H, et al. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol 2022; 19:188–206.
Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res 2015; 25:981–984.
Xia D, Gu X. Plasmatic exosome-derived circRNAs panel act as fingerprint for glioblastoma. Aging (Albany NY) 2021; 13:19575–19586.
Ding C, Yi X, Chen X, et al. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. J Exp Clin Cancer Res 2021; 40:164.
Stella M, Falzone L, Caponnetto A, et al. Serum extracellular vesicle-derived circHIPK3 and circSMARCA5 are two novel diagnostic biomarkers for glioblastoma multiforme. Pharmaceuticals (Basel) 2021; 14:618.
Chen A, Zhong L, Ju K, et al. Plasmatic circRNA predicting the occurrence of human glioblastoma. Cancer Manag Res 2020; 12:2917–2923.
Chen W, Schuman E. Circular RNAs in brain and other tissues: a functional enigma. Trends Neurosci 2016; 39:597–604.
Hanan M, Soreq H, Kadener S. CircRNAs in the brain. RNA Biol 2017; 14:1028–1034.
Wang X, Cao Q, Shi Y, et al. Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p/GRB14/PDGFRα pathway as a key regulatory mechanism in Glioblastoma progression and radioresistance: functional validation and clinical theranostic significance. Int J Biol Sci 2021; 17:1061–1078.
Si J, Li W, Li X, et al. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma. Cancer Sci 2021; 112:3491–3506.
Yin K, Liu X. CircMMP1 promotes the progression of glioma through miR-433/HMGB3 axis in vitro and in vivo. IUBMB Life 2020; 72:2508–2524.
Han C, Wang S, Wang H, et al. Exosomal circ-HIPK3 facilitates tumor progression and temozolomide resistance by regulating miR-421/. Cancer Biother Radiopharm 2021; 36:537–548.
Wu X, Jiang T, Huang R, et al. LncRNA GAS8-AS1 downregulates lncRNA NEAT1 to inhibit glioblastoma cell proliferation. Brain Behav 2021; 11:e02128.
Liao Y, Zhang B, Zhang T, et al. LncRNA GATA6-AS promotes cancer cell proliferation and inhibits apoptosis in glioma by downregulating lncRNA TUG1. Cancer Biother Radiopharm 2019; 34:660–665.
Hu Y, Jiao B, Chen L, et al. Long noncoding RNA GASL1 may inhibit the proliferation of glioma cells by inactivating the TGF-β signaling pathway. Oncol Lett 2019; 17:5754–5760.
Shen L, Xu M, Wang Z, et al. Prognostic evaluation of serum long noncoding RNA H19 for endoscopic keyhole surgery or craniotomy in glioma. Ann Clin Biochem 2020; 57:365–372.
Zhang T, Wang F, Liao Y, et al. LncRNA AWPPH promotes the invasion and migration of glioma cells through the upregulation of HIF1α. Oncol Lett 2019; 18:6781–6786.
Dai B, Xiao Z, Mao B, et al. lncRNA AWPPH promotes the migration and invasion of glioma cells by activating the TGF-β pathway. Oncol Lett 2019; 18:5923–5929.
Wu X, Fan D, Chen B. LncRNA NEAT1 accelerates the proliferation, oxidative stress, inflammation, and fibrosis and suppresses the apoptosis through the miR-423-5p/GLIPR2 axis in diabetic nephropathy. J Cardiovasc Pharmacol 2022; 79:342–354.
Sun Y, Jing Y, Zhang Y. Serum lncRNA-ANRIL and SOX9 expression levels in glioma patients and their relationship with poor prognosis. World J Surg Oncol 2021; 19:287.
Hua X, Li G, Liu Z, et al. LINK-A lncRNA participates in the pathogenesis of glioma by interacting with survivin. Exp Ther Med 2019; 18:1581–1586.
Zhang Z, Yin J, Lu C, et al. Exosomal transfer of long noncoding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. J Exp Clin Cancer Res 2019; 38:166.
Shen J, Hodges TR, Song R, et al. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol Carcinog 2018; 57:137–141.
Tan SK, Pastori C, Penas C, et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Mol Cancer 2018; 17:74.
Yuan Z, Yang Z, Li W, et al. Exosome-mediated transfer of long noncoding RNA HOTAIR regulates temozolomide resistance by miR-519a-3p/RRM1 axis in glioblastoma. Cancer Biother Radiopharm 2020.
Ma XL, Zhu WD, Tian LX, et al. Long noncoding RNA TUSC7 expression is independently predictive of outcome in glioma. Eur Rev Med Pharmacol Sci 2017; 21:3605–3610.
Chen W, Xu XK, Li JL, et al. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget 2017; 8:22783–22799.
Ma W, Zhou Y, Liu M, et al. Long noncoding RNA LINC00470 in serum derived exosome: a critical regulator for proliferation and autophagy in glioma cells. Cancer Cell Int 2021; 21:149.
Min W, Dai D, Wang J, et al. Long noncoding RNA miR210HG as a potential biomarker for the diagnosis of glioma. PLoS One 2016; 11:e0160451.
Li J, Liao T, Liu H, et al. Hypoxic glioma stem cell-derived exosomes containing Linc01060 promote progression of glioma by regulating the MZF1/c-Myc/HIF1α axis. Cancer Res 2021; 81:114–128.